Validation and application of a module of the M. D. Anderson symptom inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI)

Xin Shelley Wang, Loretta A. Williams, Cathy Eng, Tito R. Mendoza, Nyma A. Shah, Karyn J. Kirkendoll, Pankil K. Shah, Peter C. Trask, Guadalupe R. Palos, Charles S. Cleeland

Research output: Contribution to journalArticle

39 Scopus citations

Abstract

BACKGROUND: The M. D. Anderson Symptom Inventory (MDASI) was developed as a brief yet comprehensive tool to assess patient-reported symptom severity and interference in patients with cancer. The authors report the development of an MDASI module for use in patients with gastrointestinal (GI) cancer (the MDASI-GI). METHODS: Patients with GI cancer (N = 184) participated in module development and validation. The process included: 1) generating GIspecific candidate items with input from GI oncologists and from qualitative interviews with patients and adding those items to the core MDASI for testing; 2) dropping candidate GI items that lacked sensitivity; 3) validating the psychometric properties (validity, reliability, sensitivity) of the resulting MDASI-GI; and 4) conducting cognitive debriefing interviews with patients to confirm the questionnaire's ease of comprehension, relevance, and acceptability. RESULTS: Five GI-specific symptom items (constipation, diarrhea, difficulty swallowing, change in taste, and feeling bloated) were added to the original 19 MDASI symptom and interference items to form the MDASI-GI. Sixty-one percent of the sample had 1 or more moderate-to-severe symptom(s) (≥5 on a severity scale from 0 to 10). Cronbach a values were .80 and .87 for symptom severity items and interference items, respectively. Known-group validity (sensitivity) was supported by the ability of the MDASI-GI to detect significant differences in symptom and interference levels according to performance status (P < .001). Cognitive debriefing demonstrated that, for patients, the MDASI-GI was an easy-to-use and understandable tool. CONCLUSIONS: The current results indicated that the MDASI-GI is a valid, reliable, and concise tool for measuring symptom severity and interference with function in patients with GI cancer.

Original languageEnglish (US)
Pages (from-to)2053-2063
Number of pages11
JournalCancer
Volume116
Issue number8
DOIs
StatePublished - Apr 15 2010
Externally publishedYes

Keywords

  • Assessment
  • Cancer
  • Gastrointestinal
  • M. D. Anderson Symptom Inventory
  • Symptoms
  • Validation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Validation and application of a module of the M. D. Anderson symptom inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI)'. Together they form a unique fingerprint.

  • Cite this

    Wang, X. S., Williams, L. A., Eng, C., Mendoza, T. R., Shah, N. A., Kirkendoll, K. J., Shah, P. K., Trask, P. C., Palos, G. R., & Cleeland, C. S. (2010). Validation and application of a module of the M. D. Anderson symptom inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer, 116(8), 2053-2063. https://doi.org/10.1002/cncr.24920